Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Trial of Ipilimumab With and Without Nivolumab in Patients With Relapsed/Refractory Classic Hodgkin Lymphoma

Next Previous
Trial Profile

A Phase II Trial of Ipilimumab With and Without Nivolumab in Patients With Relapsed/Refractory Classic Hodgkin Lymphoma

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 10 Dec 2024 According to Results presented at the 66th American Society of Hematology Annual Meeting and Exposition, Cohort 1 was closed for slow accrual (no pts enrolled). In cohort 2, patients received Ipilimumab 3 mg/kg every 3 weeks for 4 doses and then underwent restaging with positron emission tomography.
  • 10 Dec 2024 According to Results presented at the 66th American Society of Hematology Annual Meeting and Exposition, the trial was initially designed with 2 cohorts - Cohort 1 for pts with a best response of stable disease (SD) or partial response (PR) after at least 18 weeks of PD-1 mAb monotherapy and Cohort 2 for patients with progressive disease (PD) on PD-1 based treatment.
  • 10 Dec 2024 Results assessing clinical activity with Ipilimumab monotherapy in the high-risk cohort of patients with multiply relapsed cHL, presented at the 66th American Society of Hematology Annual Meeting and Exposition.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top